Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.1060497
Keywords
gastric cancer; programmed death-ligand 1; immune checkpoint inhibitor (ICI); clinical trials; tumor microenvironment
Categories
Funding
- Science and Technology Program of Zhejiang Province
- Natural Science Foundation of Zhejiang Province
- [2021c03119]
- [LQ18H160012]
Ask authors/readers for more resources
Gastric cancer is a major global cause of cancer incidence and mortality. The use of immune checkpoint inhibitors, particularly PD-L1/PD-1 inhibitors, has shown promising results in improving the prognosis of gastric cancer patients. Understanding the regulatory mechanisms of PD-L1 in gastric cancer could lead to significant progress in immunotherapy. Personalized treatment based on molecular characteristics could maximize clinical benefits and improve prognosis.
Gastric cancer (GC) is one of the main causes of cancer incidence rate and mortality worldwide. As the main breakthrough direction, the application of immune checkpoint inhibitors makes patients with GC have better prognosis, where PD-L1/PD-1 inhibitors in immunotherapy have good anti-tumor immune efficacy. Further understanding of the regulatory mechanism of PD-L1 in GC may bring substantial progress to the immunotherapy. In this review, we provide information on the endogenous and exogenous regulatory mechanisms of PD-L1 and its biological functions combined with current clinical trials of PD-L1/PD-1 inhibitors in GC. The malignant biological phenotypes caused by PD-L1 and the corresponding clinical combined treatment scheme have been reported. Identifying the biomarkers of the potential efficacy of immunotherapy and specifying the clinical immunotherapy scheme in combination with molecular characteristics of patients may maximize clinical benefits and better prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available